➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Moodys
Express Scripts
Baxter
Colorcon

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

SORILUX Drug Profile


Email this page to a colleague

« Back to Dashboard

When do Sorilux patents expire, and what generic alternatives are available?

Sorilux is a drug marketed by Mayne Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-eight patent family members in thirteen countries.

The generic ingredient in SORILUX is calcipotriene. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the calcipotriene profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sorilux

A generic version of SORILUX was approved as calcipotriene by FOUGERA PHARMS on May 6th, 2008.

  Get Started Free

Summary for SORILUX
International Patents:28
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 42
Clinical Trials: 3
Patent Applications: 4,084
Drug Prices: Drug price information for SORILUX
What excipients (inactive ingredients) are in SORILUX?SORILUX excipients list
DailyMed Link:SORILUX at DailyMed
Drug patent expirations by year for SORILUX
Drug Prices for SORILUX

See drug prices for SORILUX

Recent Clinical Trials for SORILUX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Skin Sciences, PLLCPhase 4
Mayne Pharma International Pty LtdEarly Phase 1
Tulane UniversityEarly Phase 1

See all SORILUX clinical trials

Pharmacology for SORILUX

US Patents and Regulatory Information for SORILUX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mayne Pharma SORILUX calcipotriene AEROSOL, FOAM;TOPICAL 022563-001 Oct 6, 2010 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Mayne Pharma SORILUX calcipotriene AEROSOL, FOAM;TOPICAL 022563-001 Oct 6, 2010 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Mayne Pharma SORILUX calcipotriene AEROSOL, FOAM;TOPICAL 022563-001 Oct 6, 2010 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Baxter
McKinsey
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.